100% Locally Owned, Independent and Free

100% Locally Owned, Independent and Free

Trial could be significant step forward in pursuit of new treatment for autoimmune disease

Do you have a news tip? Click here to send to our news team.

Men suffer burns in workplace incident

Two men have suffered burns in a workplace incident in the Maroochydore city centre. A Queensland Ambulance Service spokesperson said the men sustained facial, arms More

Landmark park and hut wiped out

An island park and decades-old picnic hut have fallen victim to the sea. The Lions Park day-use area has been ravaged by the elements during More

Seawall work set to begin after design finalised

Work is about to commence on a new seawall that will replace the existing structure, which has been damaged by severe weather. From Monday, Sunshine More

Club makes last-ditch effort to save struggling venue

The president of a 50-year-old hinterland club has given a “blunt” message as the establishment faces possible closure due to financial woes. The club’s committee More

Suspected arson destroys car near campground

Police are investigating a suspected arson attack that destroyed a vehicle near a popular campground. Vehicle owner Hailey Hald was camping with her fiance Tim More

Restaurant team relocates and adds cocktail lounge

The team behind a beloved hinterland tapas restaurant has relocated and opened a new European-inspired share-plate restaurant and cocktail lounge. John McMaster and Jaey Powell More

A potential new treatment for rheumatoid arthritis will be tested on the Sunshine Coast.

The University of the Sunshine Coast Clinical Trials and Servatus Biopharmaceuticals Ltd are collaborating to trial a live biotherapeutic product, which is a field of medical therapy that is advancing globally.

Principal investigator Dr Peter de Wet said rheumatoid arthritis was an autoimmune disease that occurred when the immune system mistakenly attacked the body’s tissues, affecting the joints’ lining and causing joint pain and stiffness.

“Rheumatoid arthritis can be a debilitating condition that can impact many aspects of daily living,” he said via a UniSC media release.

“We are interested to learn about the role of the gut microbiome in treating symptoms of this condition.

“And while there are various strategies to improve joint mobility and muscle strength and reduce inflammation, some treatments are ineffective or have unwanted side effects, highlighting the need for new medicines to address the condition.”

He said the trial, to be held at UniSC’s newest clinic at Birtinya, represented a significant step forward in the pursuit of a new treatment.

Clinical Trials coordinator Jacinta Trevaskis.

Dr Samantha Coulson, head of clinical research at Servatus, said the live biotherapeutic product was an exciting and promising field of medical therapies that was advancing quickly on a global scale.

Servatus has isolated select microbial species, and pre-clinical investigations suggest the potential medication may be effective in treating autoimmune and inflammatory conditions.

“The gut microbiome plays such a vital role in many diseased states including rheumatoid arthritis, as the gut bacteria and immune system have a bidirectional influence on each other,” Dr Coulson said.

By using well-defined bacterial strains, we hope to regulate the hyperactive immune response seen in rheumatoid arthritis with significantly less side effects as with many of the current drugs in the market.

The product that could make a difference.

The team is seeking participants aged between 18 and 80 with confirmed rheumatoid arthritis and who are experiencing daily joint pain and stiffness.

Participants will need to commit to up to six visits at the Birtinya clinic over about four months and they will be reimbursed for their time on the trial.

Those interested in volunteering can find more information at UniSC Clinical Trials.

Local journalists supporting local people. Help keep independent and fair Sunshine Coast news coming by subscribing to our FREE daily news feed. All it requires is your name and email at the bottom of this article.

Subscribe to SCN’s free daily news email

Hidden
This field is for validation purposes and should be left unchanged.
[scn_go_back_button] Return Home
Share